Biomarker
AssigneeIsis Innovation Limited
InventorsNathaniel Richard West, Benjamin Michael Joseph Owens, Ahmed Nabil Hegazy, Fiona Margaret Powrie
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating chronic intestinal inflammation and/or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and/or OSM receptor-β (OSMR). The invention also relates to methods for diagnosing or prognosing chronic intestinal inflammation and/or inflammatory bowel disease in an individual and for predicting whether or not an individual will respond to an anti-TNFα therapy. The methods comprise measuring OSM and/or OSMR in the individual.
Claims40
A method of treating or preventing chronic intestinal inflammation and/or inflammatory bowel disease (IBD) in an individual, the method comprising administering to the individual an antagonist of oncostatin-M (OSM) and/or OSM receptor-β (OSMR), and thereby treating or preventing chronic intestinal inflammation and/or IBD in the individual.
A method of diagnosing or prognosing chronic intestinal inflammation and/or IBD in an individual, which method comprises measuring OSM and/or OSMR in the individual, and thereby diagnosing or prognosing the chronic intestinal inflammation and/or IBD in the individual.
Products containing:
- (i) means for determining the level of OSM and/or OSMR in an individual having or suspected of having or being at risk of developing chronic intestinal inflammation and/or IBD;
- and
- (ii) an agent for treatment or prevention of chronic intestinal inflammation and/or IBD.
A method for predicting whether or not an individual will respond to an anti-tumour necrosis factor α (TNFα) therapy, which method comprises measuring OSM and/or OSMR in the individual, and thereby predicting whether or not the individual will respond to the anti-TNFα therapy.
An assay for measuring the level of OMS and/or OMSR in an individual having or suspected of having or being at risk of developing a TNFα-mediated disease, chronic intestinal inflammation and/or IBD, comprising contacting a biological sample from the individual with an agent that binds to OSM or OSMR, measuring complex formation between the agent and OSM or OSMR, optionally calculating the OSMi, comparing the measured value or the OSMi value with a reference value, and thereby predicting whether or not the individual having a TNFα-mediated disease will respond to an anti-TNFα therapy, or diagnosing or prognosing the chronic intestinal inflammation and/or IBD in the individual.
A system comprising
- (a) a measuring module for quantifying the level of OSM and/or OSMR in a biological sample from an individual having a TNFα-mediated disease, chronic intestinal inflammation and/or IBD;
- (b) a storage module configured to store data output from the measuring module and reference and/or control data;
- (c) a computation module configured to compute the value of the data output from the measuring module and the reference or control data;
- and
- (d) an output module configured to display a prediction of whether or not the individual with a TNFα-mediated disease will respond to an anti-TNFα therapy or a recommended therapy for treatment of the individual, or a diagnosis or prognosis for the individual having chronic intestinal inflammation and/or IBD, based on the value of the output data.
The method, products, assay, system or test kit of any one of the preceding claims, in which the individual is a mammal.
A method of determining the likelihood that an individual with chronic intestinal inflammation and/or IBD will need surgery, which method comprises measuring OSM and/or OSMR in the individual, and thereby determining the likelihood that the individual will need surgery.
Dependencies are inferred from the claim text.